drugset
drugset / Trial / NCT03502954

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039

NCT03502954 ↗

Phase 1 Terminated 66 enrolled Affibody Parexel · collab
RandomizedParallel-groupTriple-blindOther

Summary

The purpose of this first-in-human study is to investigate the safety and tolerability of ABY-039 after single and multiple doses in healthy volunteers.

Timeline

Start
2018-02-26
Primary completion
2020-02-01
Completion
2020-03-20

Outcome

Outcome not reported

Stopped: “Halted prematurely”

Drugs

EvaluationDrugModalityDoseRoute
Subject TIFALIBEP Protein / enzyme biologic — Intravenous

Indications

No indication recorded.